During the 24-hour event, attendees can expect interactive sessions providing access to key opinion leaders, and local subject matter experts across Biopharma, MedTech and Healthcare, who will discuss the impacts of COVID-19 and what lessons can be learned from the pandemic. Sessions will come in several formats, such as fireside chats, roundtable and panel discussions, demonstrations and more, with select sessions streaming live through Facebook, Twitter and WeChat.
Key topics that will be covered during the event include the evolution of biopharma R&D and healthcare delivery through COVID-19, deep dives into the current status and next steps for vaccines, pricing COVID-19 drugs, the response and impact within East Asia, and views from the frontlines/healthcare professionals. Additionally, insights from experts within Europe, the Americas and Asia will be incorporated throughout the event.
A snapshot of sessions and speakers include:
- Development at the Speed of Light: Pharma’s Search for a COVID-19 Vaccine; Duncan Emerton, Director, Custom Intelligence & Analytics; Michael Haydock, Senior Director, Datamonitor Healthcare
Supported using data from Informa Pharma Intelligence’s clinical, regulatory and commercial datasets, this webinar will discuss pharma’s ‘speed of light’ search for a COVID-19/SARS-CoV-2 vaccine, highlighting runners & riders, technologies being investigated, clinical development and commercial challenges.
- How to Work With The US FDA When You Can’t Meet With Them; Derrick Gingery, Senior Writer, Pink Sheet
Even as states and countries move through various stages of reopening, in-person office works seems like it will be among the last activities to resume, and that leaves sponsors needing to meet with the US FDA virtually. We’ve all adapted to teleconferencing over the past few months, but holding one with the regulator who holds the fate of your product in its hands has special challenges. Our panel of experts will help you decide the best way to approach those meetings, whether you are trying to set up a pre-IND call or are faced with the virtual advisory committee.
- Pricing of COVID-19 Drugs and Therapeutics; Astrid Kurniawan, Senior Market Access Analyst, Datamonitor Healthcare; Cathy Kelly, Senior Editor, Pink Sheet
Fireside chat with drug pricing experts discussing ethical and market considerations for pricing COVID-19 drugs, including factors pharma should be considering and how we can balance access and affordability with commercial viability.
- How Much Data Is Enough to Approve A COVID-19 Vaccine?; Sarah Karlin-Smith, Senior Writer, Pink Sheet
Two academics will take different sides of the issue and discuss whether a quick vaccine approval could risk FDA’s credibility, drive vaccine skepticism – or burnish industry’s reputation with a scientific miracle.